American Indian Living Radio
Premier Shockwave CEO and President, A. Michael Stolarski, Discusses Science Behind dermaPACE® on American Indian Living Radio
SUWANEE, GA, Oct. 9, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — SANUWAVE Health, Inc. (OTCQB: SNWV) and Premier Shockwave, Inc. are pleased to announce that Premier Shockwave, Inc. and the dermaPACE® device were featured on American Indian Living Radio during the September 24, 2018 broadcast hosted by Dr. David DeRose.
Mr. Stolarski was interviewed while at the National Tribal Public Health Summit at the Mystic Lake Casino and Resort in Prior Lake, MN, May 22 – 24, 2018. Premier Shockwave is the exclusive dermaPACE® distributor to the Indian Health Service (IHS) and Tribally operated healthcare services market for SANUWAVE Health, Inc.
Dr. DeRose began by saying he had never heard of using shock waves to treat diabetic foot ulcers. He had looked at some of the scientific photographs and found them to be “pretty impressive stuff.”
Stolarski replied that this was “very legitimate” and noted that the device was just cleared by the FDA December 28, 2017 so it is relatively new. He detailed the 336-patient double-blinded, randomly-controlled FDA study conducted without physician assisted closure and without the assistance of antimicrobial or antibacterial assistance which achieved statistical significance at 20 weeks with 100% wound closure.
Mr. Stolarski went on to say that the dermaPACE® has the potential to save the tribal healthcare system many thousands of dollars per patient by exhibiting significantly lower incidences of lower limb amputation and wound recurrence. The device is aimed at chronic wounds, or those wounds 4 weeks and older. Mr. Stolarski called it a “feel good technology” from both a cost and quality of life standpoint.
Dr. DeRose questioned the mechanism of action and compared it to other ways we “stress the body” to make it stronger. Mr. Stolarski explained that it basically creates angiogenesis to improve healing and both agreed on the analogy of stressing the body, or tissue in this case, to make it stronger or to heal it.
Dr. DeRose’s show is broadcast throughout much of the United States, not only within native American country. He asked how those interested in the technology could find out more and Stolarski indicated that anyone interested could contact him via the website at premiershockwave.com or by emailing him at firstname.lastname@example.org. He noted that Premier Shockwave is currently the sole distributor for the Indian Health Service, VAs and Military Treatment Facilities, but that SANUWAVE Health plans to start rolling out dermaPACE technology to Key Opinion Leaders throughout the United States around October 1st.
Listen to an excerpt of Dr. David DeRose’s “American Indian Living Radio” interview with A. Michael Stolarski, President and CEO of Premier Shockwave by clicking here http://www.premiershockwave.com/dermaPACE.
To listen to the full broadcast of this or other “American Indian Living Radio” programs, go to www.AmericanIndianLiving.org.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, EvoTron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
About Premier Shockwave, Inc. and Premier Shockwave Wound Care, Inc.
Premier Shockwave, Inc. is the leading shock wave company for podiatric and orthopedic applications using OssaTron® and dermaPACE® devices throughout the United States and currently serves over 30 VA Hospitals and Military Treatment Facilities in the continental United States and Alaska. Premier Shockwave, Inc. will manage the dermaPACE® business for Premier Shockwave Wound Care, Inc. For additional information about the company, please go to www.premiershockwave.com.
About Dr. David DeRose
In addition to serving as Host and Executive Producer of American Indian Living Radio, David DeRose, MD, MPH is a board-certified specialist in both Internal Medicine and Preventive Medicine. He is making a difference in Indian Country and beyond with his innovative natural approaches to chronic diseases. Check out his free on-line program for diabetes and high blood pressure at http://www.compasshealth.net/diabetes-bp/.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking stat